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Identification of a novel ligand for the ATAD2
bromodomain with selectivity over BRD4 through
a fragment growing approach†
Duncan C. Miller, ‡a Mathew P. Martin,‡b Santosh Adhikari,‡a Alfie Brennan, a
Jane A. Endicott,b Bernard T. Golding, a Ian R. Hardcastle,a Amy Heptinstall,a
Stephen Hobson,a Claire Jennings,b Lauren Molyneux,a Yvonne Ng,b
Stephen R. Wedge,b Martin E. M. Noble*b and Celine Cano*a
ATAD2 is an ATPase that is overexpressed in a variety of cancers and associated with a poor patient prog-
nosis. This protein has been suggested to function as a cofactor for a range of transcription factors,
including the proto-oncogene MYC and the androgen receptor. ATAD2 comprises an ATPase domain,
implicated in chromatin remodelling, and a bromodomain which allows it to interact with acetylated
histone tails. Dissection of the functional roles of these two domains would benefit from the availability of
selective, cell-permeable pharmacological probes. An in silico evaluation of the 3D structures of various
bromodomains suggested that developing small molecule ligands for the bromodomain of ATAD2 is likely
to be challenging, although recent reports have shown that ATAD2 bromodomain ligands can be ident-
ified. We report a structure-guided fragment-based approach to identify lead compounds for ATAD2
bromodomain inhibitor development. Our findings indicate that the ATAD2 bromodomain can accommo-
date fragment hits (Mr < 200) that yield productive structure–activity relationships, and structure-guided
design enabled the introduction of selectivity over BRD4.
Introduction
Histone proteins undergo several post translational modifi-
cations (PTMs) that affect DNA transcription, replication and
repair, and genomic architecture.1 Histone PTMs are regulated
by three groups of proteins known as writers, erasers and
readers. Bromodomains are a class of protein interaction
modules, conserved across evolution, which recognise ε-N-acetyl
lysine PTMs.2 A total of 61 bromodomains in 46 diverse proteins
have been identified in the human proteome, and these are
divided into eight structural classes. Within subfamily IV in the
structure-based classification of bromodomain-containing pro-
teins is ATAD2 (ATPase Family, AAA Domain Containing 2).
ATAD2 is overexpressed in a wide range of human cancers,
including breast, lung, and prostate carcinomas, and it is
present in low levels in normal non-tumour cells.3–5 The over-
expression of ATAD2 has been associated with a poor patient
outcome to treatment in breast,6 lung,7 ovarian,8 hepato-
cellular,9 endometrial10 and gastric11 cancers. Functionally,
ATAD2 has been shown to act as a coactivator of various tran-
scription factors including the androgen receptor (AR),4 and the
proto-oncogene MYC,5 and studies examining gene silencing of
ATAD2, using siRNA or shRNA, report it to have a role in
tumour cell proliferation and survival.3,12 These studies suggest
that ATAD2 is a potential target for cancer drug discovery, and
small-molecule inhibitors would provide insight into the pheno-
typic response to the inhibition of ATAD2.
ATAD2 comprises a four helical bundle (αZ, αA, αB, αC) and
two loops (ZA and BC). The acetyllysine binding pocket, created
by helices αB, αC and the ZA loop, is polar and shallow com-
pared to several other bromodomains.13 The ZA loop of ATAD2,
which forms a major part of the binding site is polar, whereas,
the binding site in the bromodomain BRD4 is mostly hydro-
phobic.14 The flexibility of the ZA loop coupled to the shallow
and polar nature of the binding site resulted in the druggability
of the ATAD2 bromodomain being classified as ‘difficult’.13,14
Compounds 1 and 2a–b were recently disclosed as relatively
potent inhibitors of the bromodomain of ATAD2.15–17
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Compound 1 was not selective for ATAD2 over BRD4. Enhanced
ATAD2 potency and selectivity over BRD4 was achieved in this
series through introduction of a cyclic sulfone (2a) or a difluoro-
cyclohexane moiety (2b). These groups form favourable inter-
actions with the sidechains of Arg1007 and Arg1077 in the
ATAD2 binding site, and achieve selectivity due to unfavourable
interactions with lipophilic Trp81 and Met149 sidechains in
BRD4. Compounds 3–5 were reported as ATAD2 inhibitors
arising from a fragment screen,18 but the low potency of these
fragments makes them unsuitable as chemical probes of ATAD2
function. More recently BAY-850 (6) has been reported as a
potent ATAD2 inhibitor arising from screening of a DNA-
encoded library with an unusual dimer-inducing mode of
action, although not BRD4 selectivity data was reported.19
This work describes the development of ATAD2 inhibitors
employing structure-guided optimization of a fragment hit, with
potential for development into selective chemical tools to inves-
tigate ATAD2 bromodomain function in biological systems.
Synthesis
Screening of a small targeted fragment library identified 1,6-
dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-dione 7 as a promis-
ing scaffold for the design of inhibitors of the ATAD2 bromo-
domain. Synthesis of the bicyclic template started with protec-
tion of commercially available 6-methoxy-4-methylpyridin-3-
amine 8 as its tert-butyl carbamate to give 9 (Scheme 1).
Deprotonation followed by quenching with carbon dioxide
gave 10. Acetic anhydride mediated ring closure in the pres-
ence of catalytic tetra-N-butylammonium acetate followed by
Scheme 1 Reagents and conditions: (a) Boc2O, THF, Na2CO3, THF, r.t., 42 h, 95%; (b) (i) s-BuLi, THF, −78 °C, 15 min; (ii) CO2 (dry ice), −78 °C to r.t.,
45 min, 74%; (c) Ac2O, tetrabutylammonium acetate, 65 °C, 1 h, 81%; (d) R
1 = Me: MeI, Cs2CO3, MeCN, 60 °C, 3 h, 78%; R
1 = Et: EtI, Cs2CO3, MeCN,
60 °C, 3 h, 51% (e) MeI, MeCN, 170 °C, µW, 1 h, quant; (f ) for compounds 14a–c (i) NaH, DMF, r.t., 15 min; (ii) ethyl iodide or benzyl bromide or
(2-bromoethyl)benzene, r.t., 3 h, 61% (14a), 61%; (14b), 30% (14c); For compounds 14d–f: Cs2CO3, DMF, 100 °C, µW, 30 min: 1-(2-chloroethyl)
pyrrolidine hydrochloride 40% (14d), or 4-(2-chloroethyl)morpholine hydrochloride, 82% (14e), or (2-bromoethoxy)(tert-butyl)dimethylsilane, 55%;
(14f ); (g) TBAF, THF, r.t., 18 h, 90%.
Scheme 2 Reagents and conditions: (a) RX, MeCN, 170 °C, µW, 45 min,
22–93%; (b) MeI, Cs2CO3, DMF, 100 °C, µW, 30 min, 74–94%; (c) NaOH,
EtOH, H2O, 100 °C, 23 h, 32%; Structures of 17a–q and 18a–b are given
in Tables 2 and 3.
Scheme 3 Reagents and conditions: (a) RCHO, piperidine, THF, 100 °C,
30 min, 50–88%; (b) H2, 10% Pd/C, THF, MeOH, r.t., 2 h; (c) MeI, Cs2CO3,
DMF, 50 °C, 1.5 h, 55–56% over 2 steps; (d) 4-chlorobenzyl bromide,
MeCN, 170 °C µW, 45 min, 50–64%. Structures of 22a–f are given in
Table 4.
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bis-alkylation with iodomethane or iodoethane gave 12 and 13,
respectively. Deprotection and N-alkylpyridone formation was
achieved in a single step by heating 12 with iodomethane to
give compound 7. Targets varying the N1 substituent (14a–f )
were synthesised by alkylation of 7. 14f was deprotected using
TBAF to provide 14g.
N6-Alkylated target compounds were synthesised from 12 or
13 under microwave irradiation using an array of alkyl halides
to give 15a–p and 16a–b, respectively. Subsequent N1-methyl-
ation gave compounds 17a–q and 18a–b (Scheme 2).
Diversification of the C3-position could be achieved using
Knoevenagel condensation of aldehydes with 11 to provide
19a–j in high yield (Scheme 3). Subsequent alkene reduction,
followed by methylation provided 21a–f. Treatment of meth-
oxypyridines 21a–f with benzyl bromides at high temperature
provided the target pyridones (22a–f ) in moderate yields.
Fig. 1 Binding of initial fragment hit 7. (A) Binding mode of fragment hit 7 (yellow ball and stick) bound to ATAD2 (white). ATAD2 active site residues
shown in cylinder and conserved water molecules shown as red spheres. Potential hydrogen bonding interactions shown in black dash. (B) 2D
Interaction map of 7 with the active site residues of ATAD2 represented by Lidia within Coot. (C) Isothermal titration calorimetry of 7 binding with
saturation to ATAD2. (D) ATAD2 represented in solid surface and coloured through conservation of sequence identity between ATAD2 and the first
bromodomain of BRD4.
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Results and discussion
A crystallographic screen of a small targeted library identified
pyrrolidinopyridone 7 as a fragment which bound in the
N-acetyllysine histone binding site of the bromodomain of
ATAD2 (Fig. 1A and B). Isothermal titration calorimetry (ITC)
was used to infer the binding affinity of 7 for the bromo-
domain of ATAD2, with an apparent Kd of 2.4 mM (Fig. 1C).
The pyridone carbonyl forms a hydrogen bond with the carbox-
amide sidechain of Asn1064, and another through a water-
mediated hydrogen bond to Tyr1021, with the N
6-methyl group
projecting towards a pocket containing four conserved water
molecules. This interaction network mimics the acetylated
lysine of the histone, and is consistent with small hydrophobic
Fig. 2 Overlay of the crystal structures of fragment 17a, 14a, 14b, 17c, 17d, 17f, 17k, 22e and 22c bound to ATAD2. Compounds represented in
yellow as ball and stick. Binding pocket of ATAD2 shown in transparent surface, with neighbouring residues of compound shown in stick representa-
tion. Conserved waters are represented by red spheres.
Table 1 ATAD2 inhibition data for compounds 7, 14a–g and 17a
ID R
ATAD2 IC50
a
(µM) ATAD2 LE
ATAD2 Kd
b
(µM)
BRD4 Kd
b
(µM)
7 H >1000 N/A >2000 >2000
2400c
17a Me >1000 N/A >2000 1500
14a Et >1000 N/A 1300 12.7
14b Bn 810 ± 57 0.21 >2000 1050
14c –CH2CH2Ph 868 ± 33 0.19 1400 800
14d >1000 N/A >2000 1700
14e >1000 N/A >2000 >2000
14g –CH2CH2OH >1000 N/A >2000 >2000
aHTRF format assay. b SPR format assay. c Isothermal titration calori-
metry. Ligand efficiency (LE) = 1.4(−log IC50)/N, where N is number of
non-hydrogen atoms.
Table 2 ATAD2 inhibition, SPR and BRD4 binding data for compounds
15c and 17b–d
ID R1 R2
ATAD2 IC50
a
(µM) ATAD2 LE
ATAD2 Kd
b
(µM)
BRD4 Kd
b
(µM)
17b H Pr >1000 N/A >2000 1000
15c H Bn >1000 N/A 2000 1400
17c Me Bn 681 ± 120 0.21 700 101
17d Me –CH2CH2Ph 741 ± 74 0.20 1000 161
aHTRF format assay. b SPR format assay. Ligand efficiency (LE) = 1.4
(−log IC50)/N, where N is number of non-hydrogen atoms.
Paper Organic & Biomolecular Chemistry
1846 | Org. Biomol. Chem., 2018, 16, 1843–1850 This journal is © The Royal Society of Chemistry 2018
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
Fe
br
ua
ry
 2
01
8.
 D
ow
nl
oa
de
d 
on
 0
3/
04
/2
01
8 
16
:0
8:
53
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
groups that occupy the equivalent pocket in other bromo-
domain family ligands such as the BRD4 inhibitors JQ120 and
I-BET762.21 Selectivity over other bromodomain family
members is important in the development of a tool compound
to investigate the role of the ATAD2 bromodomain in biologi-
cal systems.22 Minimizing the BET activity of an ATAD2 chemi-
cal probe is particularly necessary due to the known effects of
BET inhibitors. Thus BRD4 was selected as representative BET
family member to assess compound selectivity. The binding
orientation of 7 in ATAD2 was designated as binding mode 1
for this template. The residues that line the acetylated lysine
binding pocket of BRD4 and ATAD2 are highly conserved
(Fig. 1D), with greater divergence in the more solvent exposed
residues including the shelf region of the protein. Achieving
selectivity for ATAD2 over BRD4 would thus require identifi-
cation of fragments that extend away from the conserved core
and towards the less conserved areas.
Methylation of the N1 position (17a) resulted in a change in
binding mode (Fig. 2A), whereby the fragment core rotates and
the pyrrolidinone carbonyl now forms a hydrogen bond with
the carboxamide sidechain of Asn1064, and a second through a
water-mediated hydrogen bond to Tyr1021. In this binding
mode the N1-methyl group projects towards the conserved
water molecules. Rotation of the pyrrolidinone core allows the
pyridone carbonyl to interact through a water molecule with
the backbone NH of Asp1014 on the ZA loop. One of the C
3-
geminal methyl groups occupies a small hydrophobic pocket
formed between the sidechains of ZA-loop residues Tyr1021,
Val1018 and the Tyr1063 residue that reside next to the con-
served asparagine. Additional hydrophobic interactions are
formed with the base of the binding pocket, where Val1008 and
Ile1074 interact with the second C
3-geminal methyl group and
pyrrolidinone core, respectively. This binding orientation was
designated as binding mode 2. Intriguingly, when the N1 sub-
stituent was further elaborated to an ethyl group (14a: Fig. 2B)
the compound reverted to binding mode 1, suggesting the con-
served water-rich pocket was unable to accommodate the
larger ethyl group.
Fragments 7, 17a, and 14a bound very weakly and were
unable to displace the acetylated histone ligand sufficiently in
a homogeneous time-resolved fluorescence (HTRF) assay to
enable a Kd to be determined, although some inhibition was
observed at the highest concentration assayed (1000 µM;
Table 1). Surface plasmon resonance (SPR) was used to assess
the direct binding of the fragments and provide Kd values for
binding to both ATAD2 and BRD4. SPR can yield artefactual
data where the concentration of a small-molecular analyte
exceeds ∼250 µM, and accordingly, this was the highest con-
centration used in the assays. Where the Kd exceeded this
Table 3 ATAD2 inhibition, SPR and BRD4 binding data for compounds
17e–q
ID R
ATAD2 IC50
a
(µM) ATAD2 LE
ATAD2 Kd
b
(µM)
BRD4 Kd
b
(µM)
17e 4-CO2Me 651 ± 1 0.18 900 141
17f 4-CO2H 533 ± 40 0.19 600 1500
17g 4-CN 562 ± 67 0.20 900 142
17h 4-CONH2 680 ± 66 0.18 700 300
17i 4-SO2Me 359 ± 37 0.19 600 200
17j 4-Cl 190 ± 63 0.24 200 40
17k 4-Br 236 ± 36 0.23 138 48
17l 4-Me 274 ± 75 0.23 400 58
17m 4-CF3 179 ± 43 0.21 400 124
17n 3,4-DiCl 299 ± 28 0.21 159 65
17o 2-CN >1000 N/A >2000 300
17p 3-CN 668 ± 28 0.19 800 184
17q 2-CO2H >1000 N/A >2000 300
aHTRF format assay. b SPR format assay. Ligand efficiency (LE) = 1.4
(−log IC50)/N, where N is number of non-hydrogen atoms.
Table 4 ATAD2 inhibition, SPR and BRD4 binding data for compounds 22a–f and 18a–b
ID R1 R2 X ATAD2 IC50
a (µM) ATAD2 LE ATAD2 Kd
b (µM) BRD4 Kd
b (µM)
22a Me Bn Cl >1000 N/A 500 >2000
22b Me Cl >1000 N/A 300 1700
22c Me Cl 352 0.17 110 1500
22d Me CH2C(CH3)3 Cl 489 ± 18 0.18 125 >2000
22e Me Cl 214 0.19 500 >2000
22f Me Cl 304 ± 83 0.20 113 800
18a Et Et Cl 163 ± 23 0.22 107 1000
18b Et Et CF3 163 ± 37 0.20 300 >2000
aHTRF format assay. b SPR format assay. Ligand efficiency (LE) = 1.4(−log IC50)/N, where N is number of non-hydrogen atoms.
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limit, projected Kds were determined by extrapolation, using
the observed response units for compound binding (RU) rela-
tive to the molecular weight of a known control compound.23
Compounds 7 and 17a bound too weakly to ATAD2 to allow
Kd values to be calculated. However, 17a did show detectable
binding to BRD4. Compound 14a showed a remarkable
increase in affinity towards BRD4, reporting a Kd of 12.7 µM
and a binding constant 100-fold weaker towards ATAD2
(Table 1).
The two binding modes offered different vectors to explore
structure activity relationships (SARs) of substituents directed
towards the RVF shelf and the ZA loop. Thus a set of N1-alkyl-
ated pyrrolidinopyridones was prepared to attempt to access
this region while maintaining binding mode 1 (Table 1).
Lipophilic benzyl (14b) and phenethyl (14c) substituents
exhibited sub-millimolar HTRF IC50 values, and showed the
first detectable signs of direct binding to both ATAD2 and
BRD4 when analysed by SPR. Co-crystallisation confirmed that
14b retained binding mode 1 (Fig. 2C). Hydrophilic substitu-
ents (14d–g) gave no measurable ATAD2 inhibition or binding
in HTRF or SPR format experiments.
To attempt to exploit binding mode 2, a set of N6-alkylated
pyrrolidinopyridones were also prepared (Table 2) with N6-
benzyl (17c) and N6-phenethyl (17d) analogues giving sub-
millimolar ATAD2 IC50 values. As expected, 17c and 17d
retained binding mode 2 (Fig. 2D and E), with the benzyl
group sitting above the RVF shelf, forming a hydrophobic
interaction with the sidechain of Lys1011. Pairwise comparison
with N1-des-methyl analogue 15c confirmed the importance of
a methyl group in the conserved water pocket. 17c and 17d
bound more tightly to BRD4 than to ATAD2 in the SPR
experiments.
With the aim of improving binding affinity towards ATAD2
the sidechain of Arg1007 was targeted through substitution of
the 4-position of the N6-benzyl group. Compound 17f showed
similar ATAD2 affinity to 17c, and the co-crystal structure with
Fig. 3 Binding interactions of 18a. (A) Crystal structure of 18a (yellow ball and stick) within the histone binding site of ATAD2 shown in white ribbon,
active site residues shown in cylinder and conserved water molecules shown in red sphere. Key potential hydrogen bonding interactions shown in
black dash. (B) Direct binding data using SPR of 18a with ATAD2 (blue) and BRD4 (green). (C) Superimposition of 18a bound to ATAD2 with BRD4
showing potential steric clashes of 18a within the binding site of BRD4 (red). (D) HTRF data of improved potency within the series 17a pink, 17c blue,
18a green.
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ATAD2 (Fig. 2F) confirmed that the carboxylate did not form
the projected charge–charge interaction with Arg1007. Other
analogues bearing functionality with the potential to form
hydrogen bonds with Arg1007 gave no further improvement in
inhibition (17g–i). Lipophilic substituents at the 4-position of
the benzyl group (17j–m, Fig. 2G) provided the most potent
benzylic analogues, but continued to be selective for BRD4.
Addition of a second chloro substituent at the 3-position (17n)
resulted in a modest drop in potency. N6-Benzyl analogues
with substituents at the 2- and 3-positions of the benzylic ring
(17o–q) were prepared to attempt to introduce further inter-
actions with the ZA loop, or to favourably influence the confor-
mation of the ligand, but no further improvement in ATAD2
affinity was observed.
Attention turned to exploring substitution at the C3-
geminal dimethyl group. The pro-S methyl group occupies a
small lipophilic pocket in the ligand binding site of ATAD2,
whereas the pro-R methyl provides opportunities for fragment
growth. It was envisioned that larger substituents at the pro-R
position may occupy the cleft between the ZA and BC loops
where the substrate acetylated lysine sidechain enters the
active site, and may also provide improved selectivity over the
more sterically demanding BRD4. Synthetic chemistry to
access chiral C3 analogues that retained one methyl but
differed in the second C3 substituent proved challenging, with
mono-alkylation strategies found to be low yielding.
Knoevenagel condensation was successful when the aldehyde
coupling partner did not contain an enolisable proton, allow-
ing the synthesis of 22a–f (Table 4) as racemic mixtures.
Symmetrical C3-diethyl analogues 18a and 18b were also
prepared.
The crystal structure of 18a bound to ATAD2 (Fig. 3A)
showed that the diethyl analogues delve further into the hydro-
phobic pockets formed within the ZA-loop residues Tyr1021,
Val1018 and with Ile1074 in the base of the binding site.
Gratifyingly, these analogues resulted in a significant improve-
ment in selectivity over BRD4 while retaining ATAD2 binding
and inhibition (Table 4) (Fig. 3B).
Superimposition of the crystal structure of 18a with the first
bromodomain of BRD4 (PDB entry 2OSS) indicates that the
selectivity for ATAD2 over BRD4 may be due to a steric clash of
one of the ethyl groups with Leu94 and the other with Ile146 in
the BRD4 structure (Fig. 3C).
Conclusions
Pyrrolidinopyridone 7 was identified through crystallographic
fragment screening as a novel ligand for the ATAD2 bromo-
domain. Assessment in HTRF, ITC and SPR assays confirmed
that this was a low affinity fragment. Structure-guided frag-
ment growing at the N1, N6 and C3 substituents led to the
identification of two binding modes for this template in
ATAD2. For binding mode 1, methylation of N1, and incorpor-
ation of substituted benzyl groups at N6 led to compounds
with ATAD2 binding affinities below 200 µM (Fig. 3D), but
these compounds bound more tightly to BRD4 than to
ATAD2. Increasing steric demand at the C3 position led to
compounds 18a and 18b, retaining ATAD2 binding affinity and
activity in the HTRF biochemical assay. These C3-substituents
conferred selectivity over BRD4 through the introduction of
unfavorable interactions with lipophilic amino acid sidechains
in the more sterically demanding BRD4 N-acetyllysine binding
site.
Overall, we have demonstrated that structure-based optimi-
sation of ATAD2 fragments was able to bring millimolar hits
into a micromolar potency range. Although inhibition of
ATAD2 in the pyrrolidinopyridone series reached a plateau at
100–200 µM, we have succeeded in identifying interactions
that can enhance potency while introducing selectivity versus
BRD4. Application of these lessons might contribute to the
development of improved chemical probes of ATAD2’s role and
structure–function relationship, if applied to fragments with
superior initial ligand efficiency.
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